Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis.

Yu SJ, Yoon JH, Lee JM, Lee JY, Kim SH, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Kim CY.

Medicine (Baltimore). 2016 Aug;95(35):e4551. doi: 10.1097/MD.0000000000004551.

2.

Automatic liver tumor segmentation on computed tomography for patient treatment planning and monitoring.

Moghbel M, Mashohor S, Mahmud R, Saripan MI.

EXCLI J. 2016 Jun 27;15:406-23. doi: 10.17179/excli2016-402.

3.

Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis.

Lan T, Chang L, Rahmathullah MN, Wu L, Yuan YF.

Medicine (Baltimore). 2016 Apr;95(15):e3185. doi: 10.1097/MD.0000000000003185. Review.

5.

Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report.

Ai DL, Li BT, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q, Liu CZ, Yang N, Wang HM, Zhou L.

Oncol Lett. 2016 Jan;11(1):798-800.

6.

Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.

Chen L, Sun J, Yang X.

Cancer Lett. 2016 Jan 1;370(1):78-84. doi: 10.1016/j.canlet.2015.09.020. Review.

7.

Management of Hepatocellular Carcinoma: Current Status and Future Directions.

Au JS, Frenette CT.

Gut Liver. 2015 Jul;9(4):437-48. doi: 10.5009/gnl15022. Review. Erratum in: Gut Liver. 2015 Nov 23;9(6):811.

8.

Role of FNAC in Hepatic lesions: Risk of track metastases.

Reddy CV, Goud YG, Poornima R, Deshmane V, Madhusudhana BA, Gayathridevi M.

South Asian J Cancer. 2015 Jan-Mar;4(1):35-7. doi: 10.4103/2278-330X.149949.

9.

The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma)..

J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S3-S26. doi: 10.1016/j.jceh.2014.04.003. Review.

10.

Role of local ablative therapy for hepatocellular carcinoma.

Thandassery RB, Goenka U, Goenka MK.

J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S104-11. doi: 10.1016/j.jceh.2014.03.046. Review.

11.

Image-guided percutaneous ablation of hepatic malignancies.

Foltz G.

Semin Intervent Radiol. 2014 Jun;31(2):180-6. doi: 10.1055/s-0034-1373792. Review.

12.

Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors.

Yu H, Burke CT.

Semin Intervent Radiol. 2014 Jun;31(2):129-37. doi: 10.1055/s-0034-1373788. Review.

13.

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation.; Interventional Oncology Sans Frontières Expert Panel.; Technology Assessment Committee of the Society of Interventional Radiology,.; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe..

Radiology. 2014 Oct;273(1):241-60. doi: 10.1148/radiol.14132958.

14.

Prognostic factors for hepatocellular carcinoma recurrence.

Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D.

World J Gastroenterol. 2014 May 28;20(20):5935-50. doi: 10.3748/wjg.v20.i20.5935. Review.

15.

Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Higgins MC, Soulen MC.

Semin Intervent Radiol. 2013 Mar;30(1):74-81. doi: 10.1055/s-0033-1333656. Review.

16.

Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trends.

Donadon M, Torzilli G.

Liver Cancer. 2013 Jan;2(1):16-24. doi: 10.1159/000346421. Review.

17.

New paradigm for management of hepatocellular carcinoma by imaging.

Joo I, Choi BI.

Liver Cancer. 2012 Sep;1(2):94-109. doi: 10.1159/000342404. Review.

18.

Antitumor effect of para-toluenesulfonamide against lung cancer xenograft in a mouse model.

Gao Y, Gao Y, Guan W, Huang L, Xu X, Zhang C, Chen X, Wu Y, Zeng G, Zhong N.

J Thorac Dis. 2013 Aug;5(4):472-83. doi: 10.3978/j.issn.2072-1439.2013.08.28.

19.

Management of hepatocellular carcinoma: Enlightening the gray zones.

Mancuso A.

World J Hepatol. 2013 Jun 27;5(6):302-10. doi: 10.4254/wjh.v5.i6.302.

20.

Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.

Canavan C, Eisenburg J, Meng L, Corey K, Hur C.

Dig Dis Sci. 2013 Sep;58(9):2691-704. doi: 10.1007/s10620-013-2705-y.

Items per page

Supplemental Content

Support Center